(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2020 (10.09.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/180243 A1

(51) International Patent Classification:
C07K 14/725 (2006.01) *A61K 35/17* (2015.01)
C12N 5/0783 (2010.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/SG2020/050090

(22) International Filing Date:
27 February 2020 (27.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10201901875X 01 March 2019 (01.03.2019) SG

(71) Applicant: **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(72) Inventors: **WU, Ling**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Department of Microbiology and Immunology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **GASCOIGNE, Nicholas Robert John**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Department of Microbiology and Immunology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **BRZOSTEK, Joanna**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Department of Microbiology and Immunology, 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(74) Agent: **DAVIES COLLISON CAVE ASIA PTE. LTD.**; 10 Collyer Quay #07-01, Ocean Financial Centre, Singapore 049315 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2020/180243 A1

(54) Title: ENGINEERED IMMUNE CELLS

(57) Abstract: The present disclosure relates generally to the field of immunology. In particular, the disclosure relates to an immune cell expressing a CAR, wherein the immune cell has been modified such that the expression and/or function of LCK has been reduced or eliminated. The disclosure also relates to methods for treating a disease in a subject.